Cancer Therapy : Clinical gH 2 AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents : Results from 2 Phase I Clinical Trials of SJG-136 ( SG 2000 )

Purpose: To evaluate g-H2AX foci as a pharmacodynamic marker for DNA damage induced by DNA interstrand cross-linking drugs. Experimental Design: g-H2AX foci formationwas validated preclinically in comparisonwith the Comet assay, and evaluated pharmacodynamically in two phase I studies of different dosing schedules of the novel cross-linking agent SJG-136 (SG2000). Results: The measurement of g-H2AX foci in human fibroblasts and lymphocytes in vitrowas more than 10-fold more sensitive than Comet assay measurement of cross-linking, with peak g-H2AX response 24 hours after the peak of cross-linking. In lymphocytes from a phase I study (every three week schedule), g-H2AX foci were detectable 1 hour following the end of administration, and in all patients, maximum responsewasobserved at 24hours. Significant levels of fociwere still evident at days 8 and15 consistentwith the known persistence of the DNA damage produced by this agent. In two tumor biopsy samples, foci were detected 4 hours postinfusion with levels higher than in lymphocytes. Extensive foci formation was also observed before the third dose in cycle 1 in lymphocytes from a second phase I study (daily 3 schedule). These foci also persisted with a significant level evident before the second cycle (day 21). An increased g-H2AX response was observed during the second cycle consistent with a cumulative pharmacodynamic effect. No clear relationship between foci formation and administered drug dose was observed. Conclusion: This is the first use of g-H2AX as a pharmacodynamic response to a DNA cross-linking agent in a clinical trial setting. Clin Cancer Res; 19(3); 721–30. 2012 AACR.

[1]  V. Spanswick,et al.  Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay. , 2010, Methods in molecular biology.

[2]  R. Begent,et al.  Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[3]  L. Kèlland,et al.  Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. , 2001, Journal of medicinal chemistry.

[4]  T. A. Connors.  Alkylating agents. , 1990, Cancer chemotherapy and biological response modifiers.

[5]  E. Sausville,et al.  SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity , 2004, Cancer Research.

[6]  Y. Pommier,et al.  Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes* , 2003, Journal of Biological Chemistry.

[7]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[8]  S. Mogi,et al.  gamma-H2AX formation in response to interstrand crosslinks requires XPF in human cells. , 2006, DNA repair.

[9]  P. McHugh,et al.  The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136 , 2005, Nucleic acids research.

[10]  K M Prise,et al.  Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. , 2008, Biochemical pharmacology.

[11]  D. Loegering,et al.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. , 2009, Blood.

[12]  Yvonne A. Evrard,et al.  Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells , 2010, Clinical Cancer Research.

[13]  P. Olive,et al.  Phosphorylation of histone H2AX as a measure of radiosensitivity. , 2004, International journal of radiation oncology, biology, physics.

[14]  I. Cree,et al.  Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients , 2005, British Journal of Cancer.

[15]  C. Aquino-Parsons,et al.  γH2AX Expression in Tumors Exposed to Cisplatin and Fractionated Irradiation , 2009, Clinical Cancer Research.

[16]  Christophe E. Redon,et al.  H2AX: functional roles and potential applications , 2009, Chromosoma.

[17]  W. Bonner,et al.  γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and Recurrence , 2006, Cell cycle.

[18]  S. Guichard,et al.  Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling , 2006, Molecular Cancer Therapeutics.

[19]  M. Waring,et al.  Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. , 2005, Biochemistry.

[20]  R E Durand,et al.  Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. , 1990, Radiation research.

[21]  P. Olive,et al.  Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  E. Sausville,et al.  SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity , 2004, Cancer Research.

[23]  Yvonne A. Evrard,et al.  Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity , 2010, Clinical Cancer Research.

[24]  Kai Rothkamm,et al.  Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Olive,et al.  Radiation Sensitivity, H2AX Phosphorylation, and Kinetics of Repair of DNA Strand Breaks in Irradiated Cervical Cancer Cell Lines , 2004, Cancer Research.

[26]  M. McDevitt,et al.  A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. , 2007, Blood.

[27]  M. Kris,et al.  A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors , 2010, Cancer Chemotherapy and Pharmacology.

[28]  J. Berlin,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors , 2011, Clinical Cancer Research.

[29]  P. McHugh,et al.  Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells , 2000, Molecular and Cellular Biology.

[30]  Z. Darżynkiewicz,et al.  Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross‐linking agent cisplatin , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[31]  James H. Doroshow,et al.  Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers , 2010, Clinical Cancer Research.

[32]  A. Thompson,et al.  The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links. , 2009, Journal of the American Chemical Society.

[33]  N. Krogan,et al.  GammaH2AX and its role in DNA double-strand break repair. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.